SCHEMBL14073572

SCHEMBL14073572

O=C1COc2ccc(NC(=O)c3ccncc3)cc2N1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.63
▸ MAPT P10636 4/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ POLB P06746 1/20 0.61
▸ AHR P35869 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ TRPV1 Q8NER1 6/20 0.53
▸ GAA P10253 2/20 0.52
▸ CYP2C9 P11712 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP19A1 P11511 2/20 0.51
▸ CYP1A2 P05177 2/20 0.49
▸ MALT1 Q9UDY8 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073778 0.90 CYP3A4 (0.61) KMT2AMAPTALDH1A1POLBAHR
SCHEMBL8192718 0.87 ALDH1A1 (0.77) KMT2AMAPTALDH1A1POLBTRPV1
SCHEMBL14073600 0.87 KMT2A (0.59) KMT2AMAPTALDH1A1POLBTRPV1
SCHEMBL14073571 0.86 ALDH1A1 (0.63) KMT2AMAPTALDH1A1POLBRAB9A
SCHEMBL14073594 0.84 CYP2C9 (0.69) KMT2AMAPTALDH1A1POLBTRPV1
SCHEMBL14073031 0.84 ALDH1A1 (0.69) KMT2AMAPTALDH1A1POLBRAB9A
SCHEMBL14073656 0.83 MAPT (0.64) KMT2AMAPTALDH1A1POLBRAB9A
SCHEMBL14073480 0.82 KMT2A (0.62) KMT2AMAPTALDH1A1POLBTRPV1
SCHEMBL14073478 0.82 KMT2A (0.62) KMT2AMAPTALDH1A1POLBTRPV1
SCHEMBL14073692 0.81 ALDH1A1 (0.72) KMT2AMAPTALDH1A1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 KMT2A 2900/4885MAPT 3986/4885ALDH1A1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback